Employees: 863
Size SBC Medical (SBC) is a United States Health Care company (Miscellaneous Commercial Services) with a market value of $645M, the 2508th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.27 on 18 Nov 2026.
Performance Over six months the shares gained 94.1%, against -10.6% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 9 in its peer set.
Growth Revenue grew 6.7% over the last twelve months (peer median -3.4%); the operating margin is 39.9% (peer median -65.5%).
Valuation It trades at 11.7× forward earnings.
Price implies For today's price to make sense, revenue must grow about -16% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -22 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 29.7 points above its cost of capital (7.5% WACC).
Short interest Short interest is 0.8% of the free float (30 Oct 2026).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $190M | $174M | $205M | $194M | $0 |
| Revenue growth | — | -15% | +6% | — | — |
| Gross profit | $136M | $126M | $154M | $126M | $0 |
| EBITDA | $79.6M | $70.2M | $89.2M | $83.3M | -$543,700 |
| Net income | $51.9M | $51.0M | $46.6M | $39.4M | $552,813 |
| Free cash flow | $113M | $36.6M | $51.9M | $41.2M | -$462,820 |
| Capital expenditure | $3.45M | $2.79M | $3.41M | $11.2M | $0 |
| Total debt | $44.0M | $51.6M | $12.2M | $22.9M | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SBC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.8% | -2.5% | highest of 9 |
| 6-month return | +94.1% | -10.6% | 3rd highest of 9 |
| Distance from 52-week high | -15.2% | -42.0% | 3rd highest of 9 |
| Revenue growth (TTM) | +6.7% | -3.4% | 3rd highest of 6 |
| Operating margin | 39.9% | -65.5% | highest of 7 |
| Forward P/E | 11.7× | n/a | — |
| Growth the price implies (Req g, 7 yrs) | -15.7% | 31.9% | least demanding of 4 |
| Growth delivered (Del g) | +6.7% | +1.1% | 2nd highest of 4 |
| Hurdle (Req g minus delivered) | -22.4 pp | +30.9 pp | least demanding of 4 |
| ROIC minus cost of capital | +29.7 pp | -13.6 pp | highest of 5 |
| EV / EBITDA | 6.3× | n/a | — |
| Net debt / EBITDA | -2.0× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SBC Medical SBC | United States | $645M | +94% | +7% | 40% | 11.7× | -15.7% | +6.7% |
| Adlai Nortye Ltd. Sponsored ADR ANL | United States | $610M | -23% | n/a | -134% | n/a | n/a | n/a |
| OmniAb OABI | United States | $741M | +97% | +91% | -116% | n/a | 60.6% | -31.9% |
| Evotec EVT.DE | Germany | $532M | -46% | -5% | -15% | n/a | n/a | n/a |
| Oculis OCS | United States | $456M | -74% | n/a | n/a | n/a | n/a | n/a |
| Evolent Health EVH | United States | $445M | +2% | +14% | -1% | 9.2× | 14.0% | +15.2% |
| Tectonic Therapeutic TECX | United States | $420M | -27% | n/a | n/a | n/a | n/a | n/a |
| Silence Therapeutics PLC Sponsored ADR SLN | United States | $1.23B | +244% | -98% | -11,920% | n/a | n/a | n/a |
| Fortrea FTRE | United States | $1.98B | +50% | -3% | 2% | 21.6× | 31.9% | +1.1% |